Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD
